Tous Actualités
Suivre
Abonner Helsinn Healthcare SA

Helsinn Healthcare SA

Helsinn Group enters into a new partnership with Healthcare Businesswomen's Association (HBA)

Switzerland (ots)

Helsinn Group has entered into a new partnership with Healthcare Businesswomen's Association (HBA). HBA is the premier catalyst for the leadership development of women, to further the advancement and impact of women in healthcare worldwide. HBA accomplishes this by providing educational opportunities to develop cutting-edge industry knowledge and leadership skills; recognizing outstanding women in the industry; providing opportunities for networking, creating greater visibility for individuals in the industry and fostering mentoring relationships; and serving as a conduit for research on career advancement issues. "HBA meets Helsinn's vision and mission and we are delighted to enter this partnership with the prestigious Healthcare Businesswomen's Association and have the opportunity to help support and boost the advancement and leadership of women at an international level", said Riccardo Braglia, Helsinn Group CEO.

"We are very happy that the Helsinn group decided to associate with HBA and we look very much forward to our collaboration in Europe and the United States. Helsinn is an ideal partner for HBA", said Gabriele Matthias, HBA Europe President, after meeting with Dr. Braglia together with Gaia Piraccini, HBA Europe President-elect, and Kimberly Hart, HBA Europe Program Director. Helsinn has entered the "Teal Package" sponsorship which will open the way to many future collaborations, activities specially tailored for Helsinn, which include showcase events, speaking opportunities at HBA's Europe summits, events across Europe which bring together leading pharmaceutical and biotechnology leaders to share best practices around focused topics. As corporate partner, Helsinn can nominate a Helsinn Rising Star who will be honored by HBA during their annual Women of the Year luncheon, with an award which recognizes professionals designated by HBA corporate partner companies, because of their outstanding performance, commitment to excellence, and the energy and enthusiasm with which they approach their activities on a daily basis.

About Healthcare Businesswomen's Association

Healthcare Businesswomen's Association (HBA) is the leading non- profit global organization committed to helping women in healthcare, across all areas of functional expertise, achieve their leadership goals at every stage of their career. The HBA was founded in 1977 when five professional women recognized the need for women in healthcare to come together to exchange industry and career info and resources. Today, the HBA has fifteen chapters more than 6'000 members. The European Chapter is active in five different countries in Switzerland, France, Italy, Germany and United Kingdom. The HBA serves its expanding membership in a variety of roles and diverse areas, but remains true to its roots to further the advancement and impact of women in healthcare worldwide.

About Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland, the United States and China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn is an important player in cancer supportive care. Helsinn Group in- licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical/clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn's products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory, financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland and supplied worldwide to its customers.

Further information on Helsinn Group is available at www.helsinn.com

For more information on HBA Europe:

http://www.hbanet.org/chapters/Europe

Contact:

For Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
Phone: +41/91/985'21'21
E-Mail:Info-hhc@helsinn.com

Plus de actualités: Helsinn Healthcare SA
Plus de actualités: Helsinn Healthcare SA
  • 07.01.2013 – 13:00

    Helsinn at the 31st Annual J.P. Morgan Healthcare Conference, January 8, 2013

    Lugano (ots) - Helsinn Group is pleased to announce that tomorrow (Tuesday, January 8th, 2013) at 9am Pacific Standard Time (18:00 Swiss time), Dr. Riccardo Braglia, Helsinn Group CEO, will present an overview of the Helsinn group, its products and corporate goals at the 31st Annual J.P. Morgan Healthcare Conference, San Francisco. Dr. Braglia's presentation will be ...

  • 11.12.2012 – 16:35

    Palonosetron infusion bag launched in Japan

    Lugano, Switzerland (ots) - The Swiss pharmaceutical Helsinn Group announces today that Taiho Pharmaceutical Co. Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist (5- HT3 RA) palonosetron, has launched on the national market the 0.75mg infusion bag formulation of palonosetron hydrochloride (Aloxi®). The infusion bag is an additional formulation to the 0.75mg injectable form already marketed ...